Webinar
Cell and gene therapies – U.S. payer trends
As the indications for cell and gene therapies (CGTs) expand into more common diseases, the need for scalable, reliable pathways to improve market access for these advanced therapies becomes even more urgent. Watch the recording to hear our market access experts share key insights from exclusive interviews with US payers in active decision-making roles across diverse national and regional health plans and IDNs. Learn the latest updates on pre- and post-approval payer engagement strategies, coverage processes, decision-making timelines, and evidence requirements, and gain actionable, data-driven insights to inform your market access plan from late-stage development through commercialization and market uptake.
Key highlights
- Understand the evolving payer mindset toward high-cost, high-value therapies.
- Learn how to optimize early payer engagement and define relevant evidence packages.
- Explore differences in approach between national and regional payers and IDNs.
- Translate payer expectations into actionable market access strategies.
Introduction & Speaker:
Kim Riggs, Vice President, Commercialization Strategy & Access Solutions, Cencora
Speakers:
Louis Cicchini, Senior Director, Scientific Affairs and Strategic Partnerships, Cencora
Shaila Yoshida, Assistant Director, Value and Access Strategy (VAS), Cencora
Access the recording to learn more and stay ahead in an evolving global healthcare environment
Pardot Form
